4X69

Crystal structure of OP0595 complexed with CTX-M-44

Summary for 4X69

• Entry DOI: 10.2210/pdb4x69/pdb
• Related: 4X68
• Descriptor: Beta-lactamase Toho-1, (2S,5R)-N-(2-aminoethoxy)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide, 1,2-ETHANEDIOL, ... (4 entities in total)
• Functional Keywords: hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• Biological source: Escherichia coli
• Total number of polymer chains: 2
• Total formula weight: 57272.68

Authors

Yamada, M.,Watanabe, T. (deposition date: 2014-12-07, release date: 2015-07-01, Last modification date: 2024-10-23)

Primary citation

Morinaka, A.,Tsutsumi, Y.,Yamada, M.,Suzuki, K.,Watanabe, T.,Abe, T.,Furuuchi, T.,Inamura, S.,Sakamaki, Y.,Mitsuhashi, N.,Ida, T.,Livermore, D.M.
OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer'
J.Antimicrob.Chemother., 70:2779-2786, 2015

PubMed Abstract: The production of a growing diversity of β-lactamases by Gram-negative bacteria challenges antimicrobial chemotherapy. OP0595, discovered separately by each of Meiji Seika Pharma and Fedora Pharmaceuticals, is a new diazabicyclooctane serine β-lactamase inhibitor that also acts as an antibiotic and as a β-lactamase-independent β-lactam 'enhancer'.

PubMed: 26089439
DOI: 10.1093/jac/dkv166

Experimental method

X-RAY DIFFRACTION (1.42 Å)